智通财经APP获悉，香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团(06628)1万 股，每股作价2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为 8.4%。 ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Insights - The updated efficacy analysis of osemitamab in combination with nivolumab and CAPOX shows promising results in patients with advanced gastric/gastroesophageal junction cancer, particularly those with higher CLDN18.2 expression [1][2][4] Efficacy Analysis - In a cohort of 26 patients with CLDN18.2 expression ≥40%, the median progression-free survival (PFS) was 16.6 months, with an overall response rate (ORR) of 68% and a median duration of response (DoR) of 18 months at a median follow-up of 25.8 months [2] - Better PFS outcomes were observed in patients with higher CLDN18.2 expression compared to lower expressors, indicating consistent treatment benefits across different PD-L1 expression subgroups [2] Safety Profile - The safety profile of the osemitamab combination regimen is consistent with previous presentations, indicating it is well tolerated [3] Expert Commentary - Clinical experts highlight the significance of the consistent benefits across PD-L1 subgroups, suggesting that the osemitamab regimen may provide meaningful improvements for a broad patient population with advanced G/GEJ cancer [4] - The ongoing strength of clinical signals reinforces the potential of osemitamab to offer effective treatment options for patients [4] Product Information - Osemitamab is a high-affinity humanized anti-CLDN18.2 monoclonal antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and has shown potent anti-tumor activities in preclinical models [5] - It has received Orphan Drug Designation in the U.S. for treating gastric or gastroesophageal junction and pancreatic cancer [5] Company Overview - Transcenta Therapeutics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics, with integrated capabilities in discovery, research, development, and manufacturing [6][7] - The company has established a global presence with facilities in Suzhou and Hangzhou, and clinical development centers in China, the U.S., and Europe [7]

Core Insights - The company announced promising clinical results for osemitamab in combination with nivolumab and CAPOX as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma, presented at the ESMO Asia Congress 2025 [1][2] Group 1: Clinical Trial Results - The updated efficacy analysis from the TranStar102 trial showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known [1] - The median duration of response (mDoR) was reported at 18 months, indicating significant clinical benefits from the treatment [1] - Higher CLDN18.2 expression patients demonstrated better PFS regardless of PD-L1 expression levels, suggesting consistent potential therapeutic benefits [1] Group 2: Safety and Clinical Benefit - The safety profile of osemitamab was consistent with previously reported data from the ASCO 2025 conference, indicating good safety and tolerability [2] - The principal investigator highlighted the consistent clinical benefits across different PD-L1 subgroups, suggesting the treatment could provide significant improvements for advanced gastric or gastroesophageal junction adenocarcinoma patients [2] - The global clinical development executive vice president of the company expressed optimism about the strong clinical benefit signals and the potential of osemitamab to offer substantial benefits to patients in need of more effective treatment options [2]

Core Insights - The study results presented at the ESMO Asia Congress 2025 indicate that the combination therapy of osemitamab with nivolumab and CAPOX shows promising clinical benefits for patients with advanced gastric or gastroesophageal junction adenocarcinoma [1][2] Group 1: Clinical Efficacy - The updated efficacy analysis from the TranStar102 trial shows a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and known PD-L1 CPS [1] - The median duration of response (mDoR) is reported to be 18 months, indicating sustained efficacy of the treatment [1] - Higher CLDN18.2 expression correlates with better PFS outcomes regardless of PD-L1 expression levels, suggesting consistent therapeutic benefits across different patient subgroups [1] Group 2: Safety and Tolerability - The safety profile of the combination therapy remains consistent with previously reported data, indicating good tolerability and safety [1][2] - The treatment is expected to provide significant clinical benefits to patients who urgently need more effective treatment options for advanced gastric or gastroesophageal junction adenocarcinoma [2]

Core Insights - The company announced positive results from the TranStar102 clinical trial, which evaluated osemitamab in combination with nivolumab and CAPOX for the treatment of gastric or gastroesophageal junction adenocarcinoma [1][2] - The updated efficacy analysis showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among patients with high CLDN18.2 expression [1] - The results indicate that the treatment benefits of osemitamab are consistent across different PD-L1 expression subgroups, suggesting its potential effectiveness for a broader patient population [2] Efficacy Analysis - The study involved 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known, with a median follow-up of 25.8 months [1] - The median duration of response (mDoR) was reported at 18 months, highlighting the durability of the treatment response [1] - The analysis confirmed that higher CLDN18.2 expression correlates with better PFS outcomes, regardless of PD-L1 expression levels [1] Safety Profile - The safety characteristics of the treatment were consistent with previously reported data from the ASCO 2025 conference [2] - The combination therapy demonstrated good safety and tolerability, reinforcing its potential as a first-line treatment option for advanced gastric or gastroesophageal junction adenocarcinoma [2] - The clinical benefits observed in the study are expected to provide significant improvements for patients in need of more effective treatment options [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，osemitamab聯合納武利尤單抗與CAPOX作 為胃或胃食管結合部腺癌(TranStar102)一線治療的I/II期臨床試驗(Transtar102)G 隊列基於CLDN18.2和PD-L1表達的更新療效分析。該研究結果以壁報形式（摘 要編號：#299P）亮相於在新加坡舉行的歐洲腫瘤內科學會亞洲年會(ESMO Asia Congress 2025)。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 創勝醫藥於ESMO Asia公佈osemitamab三聯療法一線治療胃或胃食管 結合部腺癌的I/II期(Transtar102)更新療效數據 • 公佈數據表明，對於CLDN18.2較高表達患者，無論其PD-L1表達水平如何， 均取得了令人鼓舞的療效結果－中位無進展生存期 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Core Viewpoint - The chairman of the board, Qian Xueming, has increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 2.5 per share, totaling HKD 50,000, which indicates confidence in the company's future prospects [1] Summary by Category - **Shareholding Increase** - Qian Xueming acquired 20,000 shares of Chuangsheng Group at HKD 2.5 each, amounting to a total investment of HKD 50,000 [1] - Following this transaction, his total shareholding in the company has risen to 38.02 million shares, representing an ownership stake of 8.4% [1]

Core Viewpoint - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 2.5 per share, totaling HKD 50,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Shareholding Activity** - Qian Xueming's latest shareholding after the purchase is 38.02 million shares, representing an ownership stake of 8.4% in Chuangsheng Group [1]